Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

OBN BioLearn: ‘Presenting with Impact’ course

This full-day, in-person course is designed to help professionals deliver high-quality, high-impact presentations with confidence and clarity. Through a mix of practical exercises and expert [...]

Go to Top